SAGE Sage Therapeutics, Inc.

71.63
+1  (2%)
Previous Close 70.27
Open 70.52
Price To book 7.10
Market Cap 2.67B
Shares 37,270,000
Volume 233,651
Short Ratio 5.66
Av. Daily Volume 559,968

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
SAGE-547 (202C)
Postpartum Depression - moderate
Phase 2 initiation announced December 19, 2016. Top-line data from open-label trial released February 13, 2017, with placebo part of trial to be initiated 1H 2017.
SAGE-217
Major Depressive Disorder (MDD)
Phase 2 initiation announced December 13, 2016. Data from Part A of trial due 1H 2017.
SAGE-217
Parkinson’s disease (PD)
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE-217
Postpartum depression (PPD)
Phase 3 data due 2H 2017.
SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data due 1H 2017.
SAGE-547
SRSE
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
SAGE-217
Essential tremor